Literature DB >> 10799870

Systemic immune deviation in the brain that does not depend on the integrity of the blood-brain barrier.

H Wenkel1, J W Streilein, M J Young.   

Abstract

OVA injected into the brain of normal mice evoked a deviant immune response (brain-associated immune deviation (BRAID)) that was deficient in OVA-specific delayed-type hypersensitivity. This response was not dependent on an intact blood-brain barrier since BRAID was induced even when OVA was injected into a newly created lesion site with extensive BBB leakage. However, newly activated microglia at the injection site 2 days after ablation of the striatum correlated with the loss of BRAID. At day 4 after trauma, when activated microglia were only visible further away from the injection site, BRAID was again able to be induced. In contrast to immune deviation elicited via the eye, an intact spleen was not required for BRAID, nor was BRAID adoptively transferable with spleen cells. In contrast i.v. injection of cervical lymph node cells harvested 8 days after OVA injection into the striatum was able to transfer BRAID into naive animals. Together, these data indicate that immune privilege in the brain is actively maintained and is mediated by an immune deviation mechanism that differs from eye-derived immune deviation and arises even when the BBB is compromised.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10799870     DOI: 10.4049/jimmunol.164.10.5125

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

Review 1.  CNS immune privilege: hiding in plain sight.

Authors:  Monica J Carson; Jonathan M Doose; Benoit Melchior; Christoph D Schmid; Corinne C Ploix
Journal:  Immunol Rev       Date:  2006-10       Impact factor: 12.988

Review 2.  Failed central nervous system regeneration: a downside of immune privilege?

Authors:  Ingo Bechmann
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

Review 3.  Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain.

Authors:  Burkhard Becher; Ingo Bechmann; Melanie Greter
Journal:  J Mol Med (Berl)       Date:  2006-06-14       Impact factor: 4.599

4.  Tolerogenic effect of fiber tract injury: reduced EAE severity following entorhinal cortex lesion.

Authors:  Leman Mutlu; Christine Brandt; Erik Kwidzinski; Birgit Sawitzki; Ulrike Gimsa; Jacqueline Mahlo; Orhan Aktas; Robert Nitsch; Marloes van Zwam; Jon D Laman; Ingo Bechmann
Journal:  Exp Brain Res       Date:  2006-11-08       Impact factor: 1.972

5.  Transgenic expression of CTLA4-Ig by fetal pig neurons for xenotransplantation.

Authors:  Caroline Martin; Martine Plat; Véronique Nerriére-Daguin; Flora Coulon; Svetlana Uzbekova; Eric Venturi; Françoise Condé; Jean-Michel Hermel; Philippe Hantraye; Laurent Tesson; Ignacio Anegon; Benoit Melchior; Marc Peschanski; Brigitte Le Mauff; Françoise Boeffard; Solène Sergent-Tanguy; Isabelle Neveu; Philippe Naveilhan; Jean-Paul Soulillou; Michel Terqui; Philippe Brachet; Bernard Vanhove
Journal:  Transgenic Res       Date:  2005-08       Impact factor: 2.788

Review 6.  Glial grafting for demyelinating disease.

Authors:  V Tepavcević; W F Blakemore
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

Review 7.  CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease?

Authors:  Kavon Rezai-Zadeh; David Gate; Terrence Town
Journal:  J Neuroimmune Pharmacol       Date:  2009-08-11       Impact factor: 4.147

Review 8.  Macrophages in Alzheimer's disease: the blood-borne identity.

Authors:  David Gate; Kavon Rezai-Zadeh; Dominique Jodry; Altan Rentsendorj; Terrence Town
Journal:  J Neural Transm (Vienna)       Date:  2010-06-02       Impact factor: 3.575

9.  Intracerebral infection with murine cytomegalovirus induces CXCL10 and is restricted by adoptive transfer of splenocytes.

Authors:  Maxim C-J Cheeran; Genya Gekker; Shuxian Hu; Xinan Min; Diana Cox; James R Lokensgard
Journal:  J Neurovirol       Date:  2004-06       Impact factor: 2.643

10.  Ocular immune privilege.

Authors:  A W Taylor
Journal:  Eye (Lond)       Date:  2009-01-09       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.